📇 Rhumatologue · LA ROCHE SUR YON CEDEX 9 · (85) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
97.1 rhumatos / 100 000 hab. — département bien doté
5 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
5
5 articles ont été cités au moins 5fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
147
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
7
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
4
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Universitaire de La Réunion
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Correction: Neurological manifestations in patients with VEXAS syndrome
2025ArticleJournal of Neurology
Neurological manifestations in patients with VEXAS syndrome
2025ArticleJournal of Neurology
Nonischemic Cardiac Manifestations in VEXAS Syndrome
2024ArticleJAMA Network Open
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
2024ArticleAnnals of the Rheumatic Diseases
Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura
2024ArticleBritish Journal of Haematology
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
2023ArticleRMD Open
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients
2022ArticleRheumatology
Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported Outcomes
2020ArticleHealth and Quality of Life Outcomes
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHD SITE LA ROCHE SUR YON
LES OUDAIRIES BD STEPHANE MOREAU, 85925 LA ROCHE SUR YON CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Annals of the rheumatic diseases · 2024
Rheumatology (Oxford, England) · 2022
AbstractObjectiveTo assess the safety and the efficacy of TNF-α antagonists and tocilizumab in patients with Takayasu arteritis (TAK).MethodsA total of 209 patients with TAK [median age 29 years (interquartile range 7–62)], 186 (89%) females] were included. They received either TNF-α antagonists [n = 132 (63%) with 172 lines; infliximab (n = 109), adalimumab (n = 45), golimumab (n = 8), certolizumab (n = 6) and etanercept (n = 5)] or tocilizumab [n = 77 (37%) with 121 lines; i.v. and s.c. in 95 and 26 cases, respectively].ResultsA complete response at 6 months was evidenced in 101/152 (66%) patients on TNF-α antagonists and 75/107 (70%) patients on tocilizumab. Age ≥30 years [odds ratio 2.09 (95% CI 1.09, 3.99)] was associated with complete response, whereas vascular signs [OR 0.26 (95% CI 0.1, 0.65)], baseline prednisone ≥20 mg/day [OR 0.51 (95% CI 0.28, 0.93)] were negatively associated with the complete response to TNF-α antagonists or tocilizumab. During a median follow-up of 36 months, 103 relapses were noted. Supra-aortic branches and thoracic aorta involvement [HR 2.44 (95% CI 1.06, 5.65) and 3.66 (1.18, 11.4), respectively] and systemic signs at baseline [HR 2.01 (95% CI 1.30, 3.11)] were significantly associated with relapse. The cumulative incidence of treatment discontinuation and relapse were similar in TNF-α antagonists and tocilizumab. Fifty-eight (20%) adverse effects occurred on biologic targeted therapies [37 (21%) on TNF-α antagonists and 21 (17%) on tocilizumab (P = 0.4), respectively].ConclusionThis large multicentre study shows high efficacy of biologic targeted treatments in refractory TAK. Efficacy, relapse and drug retention rate were equivalent with TNF-α antagonists and tocilizumab.
Health and quality of life outcomes · 2020
Abstract Background Using a real dataset, we highlighted several major methodological issues raised by the estimation of the Minimal Clinically Important Difference (MCID) of a Patient-Reported Outcomes instrument. We especially considered the management of missing data and the use of more than two times of measurement. While inappropriate missing data management and inappropriate use of multiple time points can lead to loss of precision and/or bias in MCID estimation, these issues are almost never dealt with and require cautious considerations in the context of MCID estimation. Methods We used the LIGALONGO study (French Randomized Controlled Trial). We estimated MCID on the SF-36 General Health score by comparing many methods (distribution or anchor-based). Different techniques for imputation of missing data were performed (simple and multiple imputations). We also consider all measurement occasions by longitudinal modeling, and the dependence of the score difference on baseline. Results Three hundred ninety-three patients were studied. With distribution-based methods, a great variability in MCID was observed (from 3 to 26 points for improvement). Only 0.2 SD and 1/3 SD distribution methods gave MCID values consistent with anchor-based methods (from 4 to 7 points for improvement). The choice of missing data imputation technique clearly had an impact on MCID estimates. Simple imputation by mean score seemed to lead to out-of-range estimate, but as missing not at random mechanism can be hypothesized, even multiple imputations techniques can have led to an slight underestimation of MCID. Using 3 measurement occasions for improvement led to an increase in precision but lowered estimates. Conclusion This practical example illustrates the substantial impact of some methodological issues that are usually never dealt with for MCID estimation. Simulation studies are needed to investigate those issues. Trial registration NCT01240772 (ClinicalTrials.gov) registered on November 15, 2010.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · Journal Article
Eviatar T, Capelusnik D, Campochiaro C, Lacombe V, et al.
British journal of haematology · 2024 · Journal Article
Weisinger J, Bouzid R, Ranta D, Woaye-Hune P, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Mekinian A, Biard L, Dagna L, Novikov P, et al.
RMD open · 2023 · Multicenter Study
Mekinian A, Biard L, Lorenzo D, Novikov PI, et al.
Rheumatology (Oxford, England) · 2022 · Journal Article
Mekinian A, Biard L, Dagna L, Novikov P, et al.
Rheumatology (Oxford, England) · 2025 · Journal Article
Mekinian A, Meneses S, Biard L, Dagna L, et al.
Health and quality of life outcomes · 2020 · Journal Article
Woaye-Hune P, Hardouin JB, Lehur PA, Meurette G, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2017 · Case Reports
Brochard J, Khatchatourian L, Woaye-Hune P, Biron C, et al.
Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported Outcomes
Abstract Background Using a real dataset, we highlighted several major methodological issues raised by the estimation of the Minimal Clinically Important Difference (MCID) of a Patient-Reported Outcomes instrument. We es
Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported Outcomes
Abstract Background Using a real dataset, we highlighted several major methodological issues raised by the estimation of the Minimal Clinically Important Difference (MCID) of a Patient-Reported Outcomes instrument. We es
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).